History of research and development of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab

被引：0
|
作者：
Yoshida, Takao [1 ]
机构：
[1] Ono Pharmaceut Co Ltd, Reserch Ctr Oncol, Osaka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SE2-4
引用
收藏
页码：693 / 693
页数：1
相关论文
共 50 条
  • [21] Early Onset of Severe Interstitial Pneumonitis Associated With Anti-PD-1 Immune Checkpoint Antibody After Pleurodesis
    Haga, Sanshiro
    Sekine, Akimasa
    Hagiwara, Eri
    Kaneko, Taichi
    Ogura, Takashi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [22] First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and "the sorcerers apprentice"
    Schmid-Bindert, Gerald
    Jiang, Tao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (03) : 215 - 216
  • [23] Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takuya
    Hachiga, Kosuke
    Shichino, Shigeyuki
    Terashima, Yuya
    Toda, Etsuko
    Shand, Francis H. W.
    Kakimi, Kazuhiro
    Ito, Satoru
    Matsushima, Kouji
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (06) : 631 - 640
  • [24] CALORIC RESTRICTION SENSITIZES MELANOMA TO ANTI-PD-1 IMMUNE CHECKPOINT INHIBITION
    Melucci, Alexa
    Qin, Shuyang
    Chacon, Alexander
    Jewell, Rachel
    Prieto, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A618 - A618
  • [25] Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Brahmer, Julie R.
    Gettinger, Scott N.
    Smith, David C.
    McDermott, David F.
    Powderly, John D.
    Carvajal, Richard D.
    Sosman, Jeffrey A.
    Atkins, Michael B.
    Leming, Philip D.
    Spigel, David R.
    Antonia, Scott J.
    Horn, Leora
    Drake, Charles G.
    Pardoll, Drew M.
    Chen, Lieping
    Sharfman, William H.
    Anders, Robert A.
    Taube, Janis M.
    McMiller, Tracee L.
    Xu, Haiying
    Korman, Alan J.
    Jure-Kunkel, Maria
    Agrawal, Shruti
    McDonald, Daniel
    Kollia, Georgia D.
    Gupta, Ashok
    Wigginton, Jon M.
    Sznol, Mario
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26): : 2443 - 2454
  • [26] DURVALUMAB Human anti-PD-L1 monoclonal antibody Immune checkpoint inhibitor Oncolytic
    Cole, P.
    DRUGS OF THE FUTURE, 2014, 39 (12) : 843 - 847
  • [27] Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice
    Ito, Satoru
    Matsushima, Kouji
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Hachiga, Kosuke
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takumi
    CANCER RESEARCH, 2015, 75
  • [28] Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs)
    Shah, Neil J.
    Ma, Barbara T.
    Kelly, William J.
    Belouali, Anas
    Serzan, Michael T.
    Gonzalez, Sebastian Ochoa
    Colton, Bradley
    Janni, Megan M.
    Knoedler, Alice R.
    Blackburn, Matthew
    Puthiamadathil, Jeevan
    Madhavan, Subha
    Kumar, Pallavi P.
    Liu, Stephen V.
    Gibney, Geoffrey Thomas
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer
    Bullock, Kennady K.
    Richmond, Ann
    CANCERS, 2024, 16 (12)
  • [30] ADOPTIVE TRANSFER OF LYMPHOKINE ACTIVATED NK CELLS IN COMBINATION WITH ANTI-PD-1 IMMUNE CHECKPOINT INHIBITOR IN THERAPY OF GLIOBLASTOMA
    Shevtsov, M.
    Pitkin, E.
    Nikolaev, B.
    Yakovleva, L.
    Marchenko, Y.
    Guzhova, I.
    Margulis, B.
    Multhoff, G.
    NEURO-ONCOLOGY, 2018, 20 : 278 - 278
12345